Pharmacological Interventions in Cerebral Ischemia

Pharmacological approaches to cerebral ischaemia have evolved from acute revascularisation strategies towards multifaceted neuroprotective and restorative therapies. While thrombolytic agents and mechanical thrombectomy remain pivotal in early reperfusion, growing emphasis is placed on targeting excitotoxicity, oxidative stress, neuroinflammation and apoptotic pathways. Ion-channel modulators, antioxidants and anti-inflammatory compounds aim to preserve neuronal viability and maintain blood–brain barrier integrity in the subacute and chronic phases. Emerging efforts focus on second-messenger systems such as cyclic GMP (cGMP) and cyclic AMP (cAMP), microglial and astrocyte modulation, and improved drug delivery across the barrier. Translational challenges include defining therapeutic windows, optimising dosing, and demonstrating clinical efficacy beyond preclinical success. Global burden and unmet clinical need drive a pipeline of small molecules and biologics poised to complement reperfusion, with the goal of enhancing functional recovery and reducing long-term disability.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Interventions in Cerebral Ischemia publication trend

The graph below shows the total number of articles in pharmacological interventions in cerebral ischemia across all publications each year (not limited to Nature Index journals).

Technical terms

Middle cerebral artery occlusion (MCAO): An experimental model of focal cerebral ischaemia achieved by blocking the middle cerebral artery to mimic stroke.

Phosphodiesterase 5 (PDE5) inhibitor: A class of drugs that prevent degradation of cyclic GMP, thereby enhancing vasodilation and intracellular neuroprotective signalling.

cGMP: Cyclic guanosine monophosphate, a second messenger crucial for vascular smooth muscle relaxation and modulation of neuronal survival pathways.

Neuroinflammation: The coordinated inflammatory response within the central nervous system involving glial cells and cytokines following ischaemic injury.

Blood–brain barrier (BBB): The specialised endothelial interface that regulates the selective passage of molecules between the blood and the brain parenchyma.

References

1. Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in rats. Neurotherapeutics (2024).
2. Effects of Sildenafil on Cognitive Function Recovery and Neuronal Cell Death Protection after Transient Global Cerebral Ischemia in Gerbils. Biomedicines (2024).
3. The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS). Molecular and Cellular Biochemistry (2023).